ENDRA Life Sciences(US:NDRA)2025-08-14 20:11Financial Performance - The net loss for the three months ended June 30, 2025, was $1,225,912, an improvement from a net loss of $2,229,153 for the same period in 2024[120]. - The net loss for the six months ended June 30, 2025, was $2,262,242, an improvement from a net loss of $5,004,853 for the same period in 2024[128]. - As of June 30, 2025, the company had an accumulated deficit of $105,700,341 and cash of $1,808,574, indicating a need for additional funding to continue operations[129]. - The company used $2,406,844 in cash for operating activities during the six months ended June 30, 2025, primarily due to the net loss[132]. Expenses - Research and development expenses decreased by 47% to $381,061 for the three months ended June 30, 2025, compared to $716,366 for the same period in 2024[116]. - Sales and marketing expenses decreased by 58% to $68,834 for the three months ended June 30, 2025, compared to $162,952 for the same period in 2024[117]. - General and administrative expenses decreased by 37% to $851,195 for the three months ended June 30, 2025, compared to $1,351,535 for the same period in 2024[118]. - Research and development expenses for the six months ended June 30, 2025, were $909,746, a decrease of 48% from $1,757,892 for the same period in 2024[124]. - Sales and marketing expenses decreased by $263,787, or 66%, to $137,825 for the six months ended June 30, 2025, compared to $401,612 for the same period in 2024[125]. - General and administrative expenses decreased by $1,129,089, or 40%, to $1,722,801 for the six months ended June 30, 2025, compared to $2,851,890 for the same period in 2024[126]. Other Income and Financing - Other income increased by $30,915, or 473%, to $37,395 for the six months ended June 30, 2025, compared to $6,541 for the same period in 2024[127]. - Financing activities provided $1,003,218 in proceeds from issuances of common stock for the six months ended June 30, 2025, compared to $1,148,470 for the same period in 2024[134]. Future Plans and Strategies - The company plans to incur research and development expenses for the foreseeable future as it continues the development of TAEUS and pursues FDA approval[103]. - The company aims to establish key biomarkers for metabolic diseases management and emerging GLP-1 therapies through its TAEUS technology[95]. - The company plans to advance the engineering design and development of its TAEUS technology and complete regulatory filings for marketing approval of its NAFLD TAEUS application in the U.S.[137]. - The company anticipates significant future expenses and will need to raise substantial additional capital to complete the commercialization of its TAEUS applications[135]. - The company has no committed external sources of funds except for the February 2024 ATM Agreement, which may be limited by registration statement rules[135]. Cryptocurrency Strategy - The company has not yet implemented its cryptocurrency treasury strategy and has not acquired any cryptocurrency as of the report date[98]. - The company anticipates continued costs associated with being a public company, including compliance with Nasdaq and SEC requirements[105].